NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase, CelleRx, and DERMAdoctor. The company was founded by Ramin Najafi on January 19, 2000 and is headquartered in Emeryville, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NovaBay Pharmaceuticals reports strong Q2 performance amidst market expansion

NovaBay Pharmaceuticals demonstrated strong performance in Q2 2024, driven by growth in eyecare products and improved gross margin.
While facing challenges such as net losses and low cash reserves, the company is focused on strategic transactions and market opportunities.
With a clear focus on the U.S. dry eye market and sales optimization, NovaBay is poised for continued growth and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase, CelleRx, and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.

NovaBay Pharmaceuticals Inc (NYSE: NBY) has agreed to acquire DERMAdoctor LLC, a privately-held company that commercializes dermatologist-developed skincare products, for $15.0 million. The deal value includes $12.0 million in cash and an additional $3 million in earnout payments contingent upon the DERMAdoctor business achieving predetermined financial targets for the 2022 and the 2023 fiscal years.

NovaBay Acquires Skincare-Focused Firm For $15M

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #DERMAdoctor--NovaBay Pharmaceuticals Signs Agreement to Acquire DERMAdoctor

NovaBay Pharmaceuticals Signs Agreement to Acquire DERMAdoctor

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that management will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021. The company presentation will be posted to the “Events” page on the company website. “We are excited about our future prospects for growth and profitability through combined organic growth and executing on our strategy to acquire or license products that allow us to levera

NovaBay Pharmaceuticals to Present at the H.C. Wainwright 23nd Annual Global Investment Conference

EMERYVILLE, Calif. & CYPRESS, Texas--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces an agreement with Okra Limited to distribute their Zocular dry eye products alongside Avenova in NovaBay's physician-dispensed sales channel. Products sold under the Zocular brand were developed by Okra Limited CEO Peter Pham, MD, a board-certified ophthalmologist, and are all complementary to A

NovaBay Pharmaceuticals to Distribute Zocular® Dry Eye Products

NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q2 2021 Results - Earnings Call Transcript

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and six months ended June 30, 2021 and provides a business update. “Unit sales reached a new quarterly record as more people than ever before are using and benefitting from Avenova,” said Justin Hall, President and CEO of NovaBay Pharmaceuticals. “We also are reporting record revenue from the over-the-counter channel that increased sequentially from the first quarter

NovaBay Pharmaceuticals Reports Second Quarter 2021 Financial Results

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces it will report financial results for the three and six months ended June 30, 2021 after market close on Thursday, August 12, 2021 and will hold an investment community conference call that day at 4:30 p.m. Eastern time. Date/Time: Thursday, August 12, 4:30 p.m. ET / 1:30 p.m. PT   Pre-Registration: Participants can pre-register for the conference call here:   Callers who pre-register will be given

NovaBay Pharmaceuticals to Hold Second Quarter 2021 Conference Call on August 12

BSQUARE

Iterum Therapeutics Plc

Top high volume penny stocks to watch in August 2021 The post 4 Hot Penny Stocks to Watch With High Volume in August appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Hot Penny Stocks to Watch With High Volume in August

Dyadic International Inc., DE

SINTX Technologies Inc

Exela Technologies

With earnings season in full swing, which penny stocks are investors watching right now? The post Best Penny Stocks to Buy Now?

Best Penny Stocks to Buy Now? 4 to Watch During Earnings Season

Staffing 360 Solutions

Which penny stocks are you watching as we turn the corner on July The post Best Penny Stocks To Buy This Week? 3 To Watch At The End Of July appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy This Week? 3 To Watch At The End Of July

Arbutus Biopharma

Aerpio Pharmaceuticals Inc

Corbus Pharmaceuticals Holdings

Digital Brands Group Inc

9F Inc - ADR

NexGen Energy

Why investors are watching these 7 penny stocks right now The post Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova® for the eye care market and CelleRx® for the beauty market, announces that management will participate at the upcoming investment conferences: Ladenburg Thalmann Virtual Healthcare Conference being held July 13-14. Management will present a company overview on July 14 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). A webcast of the presentat

NovaBay Pharmaceuticals to Participate in Two July Investment Conferences

Amarin Corporation Plc

Cocrystal Pharma

Elite Education Group International Ltd

Luokung Technology Corp

Meten Holding Group Ltd.

Regulus Therapeutics

Which penny stocks are worth buying next month? Check these 7 out for your watchlist The post 7 Hot Penny Stocks to Watch That Are Trending Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Hot Penny Stocks to Watch That Are Trending Right Now

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focusing on expanding its presence in the eye and skin care market, announces the availability of i-Chek Illuminated Eye Examination Mirror on Amazon. i-Chek is a unique portable, lightweight, handheld lighted mirror featuring 10x magnification that is specifically designed for at-home precise visual resolution and high magnification of the eyes, eyelashes and eyelids. “i-Chek is t

NovaBay Pharmaceuticals Launches First of Several New Products to Expand Avenova Line

NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q1 2021 Results - Earnings Call Transcript

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three months ended March 31, 2021 and provides a business update. “Our focus on the OTC channel is paying off as Avenova direct-to-consumer quarterly revenue exceeded $1 million for the first time with unit sales setting a new record. The OTC channel accounted for approximately 79% of Avenova revenue for the quarter, up from 51% for the prior-year period,” said Justin Hall,

NovaBay Pharmaceuticals Reports First Quarter 2021 Financial Results

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces it will report financial results for the three months ended March 31, 2021 after market close on Thursday, May 6, 2021 and will hold an investment community conference call that day at 4:30 p.m. Eastern time. Date/Time: Thursday, May 6, 4:30 p.m. ET / 1:30 p.m. PT     Pre-Registration: Participants can pre-register for the conference call here:     Callers who pre-register will be given a conferen

NovaBay Pharmaceuticals to Hold First Quarter 2021 Conference Call on May 6

NovaBay Pharmaceuticals' (NBY) CEO Justin Hall on Q4 2020 Results - Earnings Call Transcript

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and twelve months ended December 31, 2020 and provides a business update. “Avenova unit sales for the fourth quarter reached a new record, driven primarily by online orders as well as through our physician dispensed channel,” said Justin Hall, President and CEO of NovaBay Pharmaceuticals. “Product revenue for the fourth quarter increased 10% over the prior year quarte

NovaBay Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces it will report financial results for the three and 12 months ended December 31, 2020 after market close on Thursday, March 25, 2021 and will hold an investment community conference call that day at 4:30 p.m. Eastern time. Date/Time: Thursday, March 25, 4:30 p.m. ET / 1:30 p.m. PT     Pre-Registration: Participants can pre-register for the conference call here:       Callers who pre-register will b

NovaBay Pharmaceuticals to Hold 2020 Fourth Quarter and Full Year Conference Call on March 25

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova® for the eye care market and CelleRx® Clinical Reset™ for the beauty market, announces that management will hold one-on-one investor meetings at the Virtual 33rd Annual Roth Conference being held March 15-17, 2021. Investors interested in arranging a meeting with NovaBay management should contact their Roth Capital Partners sales representative or LHA I

NovaBay Pharmaceuticals to Participate in Virtual 33rd Annual Roth Conference

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #Avenova--NovaBay announces Avenova and CelleRx Clinical Reset to be available in brick-and-mortar stores.

NovaBay CEO Issues Letter to Stockholders

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #Avenova--NovaBay Pharmaceuticals announces its proprietary hypochlorous acid solution has received EPA approval for SARS-CoV-2 kill claim.

NovaBay Pharmaceuticals Now Included in EPA N Listing of Products That Kill SARS-CoV-2

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals Expands Avenova's Geographic Reach to Australia with New Exclusive Distribution Agreement

NovaBay Pharmaceuticals Expands Avenova's Geographic Reach to Australia with New Exclusive Distribution Agreement

NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q3 2020 Results - Earnings Call Transcript

News for NovaBay Pharmaceuticals Stock (NBY)